Navigation Links
Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting

CALGARY, Nov. 3 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that it has achieved positive interim results in its U.K. combination REOLYSIN(R) and docetaxel clinical trial for patients with advanced cancers.

Prof. Hardev Pandha of the Royal Surrey Hospital, U.K., presented the results at the International Society for Biological Therapy of Cancer (iSBTC) annual meeting on November 1, 2008. The meeting was held in San Diego, California from October 31 - November 2, 2008.

Fourteen patients have been treated to date in the dose escalation portion of the trial and eleven patients are evaluable for response. The detailed results are summarized in the following table:



Primary Tumour TCID(50) Cycles Best Response


Breast 1x10(10) 8 PR

CR in liver


Gastric 3x10(10) 8* PR

32% reduction in

lymph nodes


Mesothelioma 1x10(10) 6 Minor response

23% reduction in

lymph nodes


Prostate 3x10(9) 6 SD on scans

30% reduction in PSA


Squamous Cell 3x10(9) 3 Minor response

Carcinoma 26% reduction in

Head and Neck lymph node


Unknown 3x10(9) 6 SD


Pancreas 3x10(10) 6* SD


Prostate 3x10(10) 5* SD


Prostate 3x10(10) 5 SD


Melanoma 1x10(10) 4 SD


Pancreas 3x10(10) 2 SD, but progressed



* patients still on study. CR=complete response,

PR=partial response, SD=stable disease

"These are extraordinary results for a Phase I trial," said Dr. Brad Thompson, President and CEO of Oncolytics. "To see tumour stabilization or better in this patient population is highly unusual."

The trial (REO 010) has two components. The first is an open-label, dose-escalating, non-randomized study of REOLYSIN(R) given intravenously with docetaxel every three weeks. In this portion of the trial, which was completed in August 2008, standard dosages of docetaxel were delivered to patients with escalating dosages of REOLYSIN(R) intravenously. The second component of the trial includes the enrolment of a further nine patients at the top dose of REOLYSIN(R) in combination with a standard dosage of docetaxel. Patients may receive up to eight cycles of treatment in this study.

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours including bladder, lung, prostate or upper gastro-intestinal cancers that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists. The primary objective of the trial is to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN(R) when administered in combination with docetaxel. Secondary objectives include the evaluation of immune response to the drug combination, the body's response to the drug combination compared to chemotherapy alone and any evidence of anti-tumour activity.

The poster will be available today on the Oncolytics website at

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at this meeting with respect to REOLYSIN(R), the Company's expectations related to the results of trials investigating delivery of REOLYSIN(R), the Company's analysis of the results of the Phase I trial, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
2. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
3. Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium
4. Oncolytics Biotech Inc. Collaborators to Present Preclinical Combination REOLYSIN(R) and Cisplatin Research at EORTC-NCI-AACR Annual Meeting
5. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2008
6. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
7. Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale
8. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
9. Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent
10. Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial
11. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Post Your Comments:
(Date:11/25/2015)... 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced  today ... rights plan (Rights Plan) in an effort to preserve ... under Section 382 of the Internal Revenue Code (Code). ... use of its NOLs could be substantially limited if ... Section 382 of the Code. In general, an ownership ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... 25, 2015 The Global ... a professional and in-depth study on the current ... (Logo: ) , The ... including definitions, classifications, applications and industry chain structure. ... international markets including development trends, competitive landscape analysis, ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... be speaking at the following conference, and invited investors ... York, NY      Tuesday, December 1, 2015 at ... York, NY      Tuesday, December 1, 2015 at ... Healthcare Conference, New York, NY ...
Breaking Biology Technology:
(Date:11/18/2015)... 18, 2015  As new scientific discoveries deepen our ... other healthcare providers face challenges in better using that ... In addition, as more children continue to survive pediatric ... and old age. John M. Maris, M.D ... of Philadelphia (CHOP) . --> John ...
(Date:11/17/2015)... SOUTH EASTON, Mass. , Nov. 17, 2015 /PRNewswire/ ... "Company"), a leader in the development and sale of ... to the worldwide life sciences industry, today announced it ... closing of its $5 million Private Placement (the "Offering"), ... Offering to $4,025,000.  One or more additional closings are ...
(Date:11/11/2015)... 2015   MedNet Solutions , an innovative SaaS-based eClinical ... is pleased to announce that it will be a Sponsor ... event, to be held November 17-19 in Hamburg ... demonstrations of iMedNet , MedNet,s easy-to-use, proven ... has been able to deliver time and cost savings ...
Breaking Biology News(10 mins):